Nordwand Advisors’s NovoCure NVCR Stock Holding History

Nordwand Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-256,628	Closed	-$3.32M	–	154
2025 Q3	$3.32M	Hold	256,628	–	–	0.53%	56
2025 Q2	$4.57M	Hold	256,628	–	–	0.72%	41
2025 Q1	$4.57M	Sell	256,628 -55,527	-18%	-$1.26M	1.72%	5
2024 Q4	$9.3M	Sell	312,155 -2,717,669	-90%	-$57.5M	3.83%	3
2024 Q3	$47.4M	Buy	3,029,824 +1,514,824	+100%	+$27.5M	12.67%	3
2024 Q2	$26M	Hold	1,515,000	–	–	11.32%	3
2024 Q1	$23.7M	Hold	1,515,000	–	–	9.2%	3
2023 Q4	$22.6M	Hold	1,515,000	–	–	5.97%	3
2023 Q3	$24.5M	Hold	1,515,000	–	–	4.85%	3
2023 Q2	$62.9M	Hold	1,515,000	–	–	10.78%	3
2023 Q1	$91.1M	Hold	1,515,000	–	–	14.85%	3
2022 Q4	$111M	Buy	+1,515,000	New	+$114M	13.86%	3

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nordwand Advisors's NVCR Position: Q4 2025 in Review

Nordwand Advisors sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 256,628 shares — an estimated $3.32M sold.

Nordwand Advisors first reported a position in NVCR in Q4 2022 and held it in 12 quarters. The position peaked at $111M in Q4 2022. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Nordwand Advisors reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Nordwand Advisors sold 256,628 NovoCure shares in Q4 2025, an estimated $3.32M.
Nordwand Advisors first reported a position in NovoCure in Q4 2022 and held it in 12 quarters.
Nordwand Advisors's NovoCure position peaked at $111M in Q4 2022.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Nordwand Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.